These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19897252)

  • 1. Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach.
    Lipkovich IA; Deberdt W; Csernansky JG; Buckley P; Peuskens J; Kollack-Walker S; Rotelli M; Houston JP
    Psychiatry Res; 2009 Dec; 170(2-3):161-7. PubMed ID: 19897252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizoaffective disorder: a form of schizophrenia or affective disorder?
    Evans JD; Heaton RK; Paulsen JS; McAdams LA; Heaton SC; Jeste DV
    J Clin Psychiatry; 1999 Dec; 60(12):874-82. PubMed ID: 10665641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.
    Hogarty GE; Flesher S; Ulrich R; Carter M; Greenwald D; Pogue-Geile M; Kechavan M; Cooley S; DiBarry AL; Garrett A; Parepally H; Zoretich R
    Arch Gen Psychiatry; 2004 Sep; 61(9):866-76. PubMed ID: 15351765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia.
    González-Blanch C; Perez-Iglesias R; Pardo-García G; Rodríguez-Sánchez JM; Martínez-García O; Vázquez-Barquero JL; Crespo-Facorro B
    Psychol Med; 2010 Jun; 40(6):935-44. PubMed ID: 19751542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.
    Levine SZ; Rabinowitz J; Case M; Ascher-Svanum H
    J Clin Psychopharmacol; 2010 Aug; 30(4):446-9. PubMed ID: 20631562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theory of mind in schizophrenia: the role of clinical symptomatology and neurocognition in understanding other people's thoughts and intentions.
    Abdel-Hamid M; Lehmkämper C; Sonntag C; Juckel G; Daum I; Brüne M
    Psychiatry Res; 2009 Jan; 165(1-2):19-26. PubMed ID: 19073346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia.
    Velligan DI; Alphs L; Lancaster S; Morlock R; Mintz J
    Psychiatry Res; 2009 Sep; 169(2):97-100. PubMed ID: 19664826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-year outcomes in first admission adolescent inpatients: clinical and cognitive characteristics at admission as predictors.
    Pogge DL; Insalaco B; Bertisch H; Bilginer L; Stokes J; Cornblatt BA; Harvey PD
    Psychiatry Res; 2008 Jul; 160(1):47-54. PubMed ID: 18534688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom factors in early-onset psychotic disorders.
    McClellan J; McCurry C; Speltz ML; Jones K
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):791-8. PubMed ID: 12108803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asocial beliefs as predictors of asocial behavior in schizophrenia.
    Grant PM; Beck AT
    Psychiatry Res; 2010 May; 177(1-2):65-70. PubMed ID: 20163875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.
    Lambert M; Schimmelmann BG; Naber D; Eich FX; Schulz H; Huber CG; Karow A
    Pharmacopsychiatry; 2009 Nov; 42(6):277-83. PubMed ID: 19924588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson DG; Woerner MG; Alvir JM; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Bilder R; Goldman R; Lieberman JA
    Am J Psychiatry; 1999 Apr; 156(4):544-9. PubMed ID: 10200732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental and neurologic correlates of treatment response in schizophrenia.
    Whelton CL; Cleghorn JM; Atley S; Durocher GJ; MacCrimmon D
    J Psychiatry Neurosci; 1992 Mar; 17(1):15-22. PubMed ID: 1349824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.